Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24486870 | 0.86 | SMN1; SMN2 (0.31) | KMT2ASMN1; SMN2ALDH1A1PTGS2HSD17B10 | |
| SCHEMBL24486897 | 0.85 | POLB (0.31) | POLBSMN1; SMN2PTGS2 | |
| SCHEMBL24486801 | 0.83 | ALDH1A1 (0.38) | KMT2APOLBSMN1; SMN2TSHRNPSR1 | |
| SCHEMBL24487270 | 0.81 | ALDH1A1 (0.35) | KMT2APOLBSMN1; SMN2TSHRNPSR1 | |
| SCHEMBL24486900 | 0.79 | POLB (0.30) | POLB | |
| SCHEMBL24486885 | 0.78 | — | — | |
| SCHEMBL24486820 | 0.77 | CYP2D6 (0.41) | KMT2ASMN1; SMN2TSHRNPSR1ALDH1A1 | |
| SCHEMBL24486805 | 0.76 | CYP1A2 (0.41) | SMN1; SMN2ALDH1A1DRD4PTGS2HSD17B10 | |
| SCHEMBL24487265 | 0.73 | ALDH1A1 (0.38) | KMT2APOLBSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL24486869 | 0.71 | ALDH1A1 (0.36) | KMT2ASMN1; SMN2TSHRNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352325-B2 | Rapid fluorescence tagging of glycans and other biomolecules with enhanced MS signals | WATERS TECHNOLOGIES CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352325-B2 | Rapid fluorescence tagging of glycans and other biomolecules with enhanced MS signals | FUT5, FUT6, ST3GAL3 | KMT2A 2994/4885POLB 4498/4885SMN1; SMN2 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.